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Abstract
Background: Although familial clustering of functional dyspepsia (FD) has been reported, the role of genetics in
the susceptibility to FD is still not well understood. In the present study, the association between serotonin
transporter (SERT) gene (SLC6A4) polymorphism and FD was explored.
Methods: Subjects were divided into either a postprandial distress syndrome (PDS) group or an epigastric pain
syndrome (EPS) group according to the Rome III criteria. The healthy controls were those who had visited a
hospital for an annual health check-up. The presence of the SLC6A4 promoter polymorphism, 5-hydroxytryptamin
transporter gene linked polymorphic region (5-HTTLPR), was then evaluated, and logistic regression analysis was used
to test all variables.
Results: The 5-HTTLPR genotype distribution was 448 SS, 174 SL, and 24 LL in controls and 30 SS, 20 SL, and 3 LL
in FD subjects. No significant correlation was found between the 5-HTTLPR genotype and FD. When the genotypes
and subtypes of FD were exploratory evaluated, the SL genotype was significantly associated with PDS [odds ratio
(OR) = 2.24, 95% confidence interval (CI); 1.16-4.32, P = 0.034 after Bonferroni correction] compared to the SS
genotype adjusted for sex and age. Comparison of the SS genotype with the SL/LL genotype also showed a
significant association of genotype with PDS (OR = 2.32, 95% CI; 1.23-4.37, P = 0.009).
Conclusion: The present results suggest that 5-HTTLPR L allele may influence the susceptibility to PDS.
Background
Functional dyspepsia (FD) is characterized by the presence
of symptoms thought to originate in the gastroduodenal
tract in the absence of any organic or systemic disease that
explains the symptoms [1]. The precise pathophysiology of
the functional gastrointestinal disorders is still unknown.
However, several pathophysiological mechanisms have
been described as possible etiological factors: visceral
hypersensitivity [2,3], impaired proximal gastric accommo-
dation [4], delayed or early gastric emptying [5], dysfunc-
tion of the autonomic nervous system [6], and underlying
psychiatric disturbances [7]. Although risk factors for FD,
including age, sex, Helicobacter pylori infection, smoking,
and psychological disturbances, have also been reported,
the data are inconclusive [8,9].
There is increasing evidence that susceptibility to func-
tional gastrointestinal disorders is influenced by hereditary
factors. We have reported the association between G-pro-
tein b3 subunit 825TT genotype and EPS-like dyspepsia
[10]. IL-17F 7488T/C, migration inhibitory factor G173C
[11], catechol-o-methyltransferase gene val158met [12], 779
TC of CCK-1 intron 1 [13], cyclooxygenase-1 T1676C [14],
p22 phagocyte oxidase C242T [15], transient receptor
potential cation channel, subfamily V, member 1 G315C
[16], and regulated upon activation normal T cell expressed
and secreted C-28G polymorphisms have also been
reported to be associated with the development of FD or
dyspeptic symptoms in the Japanese population [17].
Serotonin (5-hydroxytryptamin, 5-HT) is an important
signaling molecule affecting gastrointestinal motor and
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5-HT is synthesized in enterochromaffin cells in the gut.
5-HT binds to 7 subclasses of serotonergic receptors dif-
ferentiated on the basis of structure, molecular mechan-
isms, and function [18]. To terminate serotonergic
action, re-uptake occurs by the serotonin transporter
protein (SERT) from the synaptic cleft. This protein is
e n c o d e db yas i n g l eg e n e( SLC6A4) on chromosome
17q11 and is composed of 14 exons [19]. There is a
44-bp insertion/deletion in the 5’-flanking promoter
region (5-HT transporter gene linked polymorphic region,
5-HTTLPR), which creates a short and a long allele
(S and L allele). The S allele of 5-HTTLPR has been
associated with lower transcriptional efficiency than the
L allele [20].
Several studies have investigated the association between
this functional polymorphism and various complex beha-
vioral traits and disorders, including anxiety [20], major
depression [21], suicide [22], smoking behavior [23], alco-
hol dependence [24], and irritable bowel syndrome
[25-32]. Only two studies have explored the association
between 5-HTTLPR polymorphism and FD. However,
there were no significant associations between them
[33,34]. We thought it necessary to undertake a large-scale
general population study. In this study, the relationship
between the 5-HTTLPR polymorphism and FD was inves-
tigated in Japanese patients, with subjects who underwent
annual health check-up acting as controls.
Methods
Subjects
A total of 77 subjects with uninvestigated dyspepsia at
Hyogo College of Medicine from June 2006 to June 2010
were enrolled. All subjects were Japanese and completed
an original self-administered questionnaire that assessed
symptoms of dyspepsia, gastroesophageal reflux disease
(GERD), and irritable bowel syndrome (IBS) according to
the ROME III criteria. Dyspeptic symptoms were defined
as pain or discomfort in the upper abdomen for the last 3
months, with symptom onset at least 6 months prior to
the check-up. Postprandial distress syndrome (PDS) was
defined as postprandial fullness and early satiation, and
epigastric pain syndrome (EPS) was defined as epigastric
pain and epigastric burning for more than 6 months with
symptoms. Age, sex, smoking, alcohol consumption, pre-
vious upper gastrointestinal studies, and previous medica-
tion were also recorded. Subjects who consumed alcohol
more than 4 days a week, regardless of the amount, were
considered to have a drinking habit. Smoking was defined
as smoking any number of cigarettes daily. As judged by
the physician, blood tests and further examinations such
as esophagogastroduodenoscopy (EGD) and abdominal
ultrasonography (US) were performed. A total of 24 sub-
jects who had significant EGD or US findings, such as
peptic ulcer disease, malignancies, gall stone, or abnormal
results in laboratory parameters including ALT or WBC,
was excluded from this study. Finally, 53 subjects were
diagnosed as having FD, of which only 3 subjects also
overlapped with IBS according to the ROME III criteria.
As controls, people visiting the Healthcare Center of
Social Insurance Shiga Hospital for an annual health
check-up were asked to participate in the study. About
80% of those who underwent an annual health check-up
from December 2007 to April 2008 agreed to participate
in the study. Of the 1000 subjects who completed the
same questionnaire, 646 subjects who did not have any
symptoms of dyspepsia were included in this study. This
study was approved by the ethics committees of both the
Hyogo College of Medicine and the Social Insurance Shiga
Hospital, and written informed consent was obtained from
all participants.
Genotyping
DNA was isolated from whole blood from 699 participants
by the alkaline lysis method using the QIAamp DNA
Blood Maxi Kit (Qiagen Inc., Valencia, CA). The poly-
morphisms in the 5-HTTLPR were identified by polymer-
ase chain reaction (PCR)-based fragment length
polymorphisms. Polymorphisms were confirmed by direct
sequencing. Oligonucleotide primers flanking the 5-
HTTLPR long polymorphic region corresponding to the
nucleotide positions 1651 to 1670 (sense 5’ GCCGCTCTG
AATGCCAGCAC 3’) and 2242 to 2265 (antisense 5’
GGAGGAACTGACC-CCTGAAAACTG 3’)w e r eu s e dt o
generate 528- and/or 572-base-pair PCR-amplified frag-
ments. Both sequences were obtained from the GenBank/
EBI Data Bank, accession number X76753. PCR amplifica-
tion was performed in a final volume of 20 μl, consisting
of 0.2 μg of genomic DNA, 400 μmol/L deoxyribonucleo-
tides, and 0.2 μmol/L of each primer. Because of the high
guanine and cytosine (GC) content in the amplified region
of the SERT gene (SLC6A4), the PCR reactions were per-
formed using the TaKaRa La Taq polymerase (0.8 U/reac-
tion) with GC Buffer I (TaKaRa Biomedicals, Shiga,
Japan). After denaturing all DNA samples at 94°C for 1
min, cycling conditions were set at 30 cycles of 94°C for
30 s, 60°C for 30 s, and 72°C for 2 min, with a 10-min
final cycle extension at 72°C. To determine the presence
of length variations of the alleles, amplified products were
electrophoresed on 2.0% agarose and visualized by ethi-
dium bromide staining.
Statistical Analysis
The median and range in each group were calculated, and
differences were compared using the nonparametric
Mann-Whitney U-test. Differences between 5-HTTLPR
genotypes and sex, smoking, or drinking were compared
by Fisher’s exact test. The distribution of alleles at each
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2 statistic of the Hardy-
Weinberg equilibrium. 5-HTTLPR genotypes were com-
pared between FD patients and controls, and the associa-
tion between specific types of FD and 5-HTTLPR
polymorphism was assessed. A logistic regression analysis
was performed to test the influence of several factors in
the association between the 5-HTTLPR polymorphism
genotype distribution and FD. P < 0.05 was considered sig-
nificant. The Bonferroni correction was applied for multi-
ple testing of each genotype.
Power of the Study
In this study, the potential association of symptoms of dys-
pepsia with 5-HTTLPR genotypes was assessed. In the
healthy Japanese population, approximately 30% are
expected to have the SL/LL genotype. Assuming that
approximately 5% of subjects have symptoms of dyspepsia,
a 20% increase in the prevalence of a genotype would be
of clinical relevance. Thus, setting a =0 . 0 5a n db = 0.80,
977 asymptomatic controls and 52 subjects with FD would
be sufficient to identify a clinically relevant difference. The
actual number of enrolled subjects (53 FD cases and 646
controls) has a power of 80% to detect the assumed differ-
ence. For the subgroup analyses for EPS (39 cases), and
PDS (42 cases), the power to identify the assumed differ-
ence is 67%, and 70%, respectively.
Results
Participant demographics and 5-HTTLPR genotype distri-
bution are summarized in Table 1. The median age of the
subjects with dyspepsia and the non-dyspeptic controls
was 52 (range, 21-82) and 45 (range, 19-78) years (P =
0.002). No significant bias was found between the groups
for sex, smoking habit, and drinking habit. The 5-HTTLPR
genotype distribution in all subjects in this study was 478
SS (68.4%), 194 SL (27.8%), and 27 LL (3.9%); this distribu-
tion was compatible with the Hardy-Weinberg equilibrium
(P = 0.195). The 5-HTTLPR genotype distribution was 448
SS (69.3%), 174 SL (26.9%), and 24 LL (3.7%) in subjects
without dyspepsia (controls), and 30 SS (56.6%), 20 SL
(37.7%), and 3 LL (5.7%) in subjects with FD; both distri-
butions were also compatible with the Hardy-Weinberg
equilibrium. The distribution of the SS/SL/LL genotypes
in the healthy controls was similar to other reports for
Japanese populations [35,36]. The distribution of allele and
genotype frequencies did not differ significantly between
males and females.
The association of genotypes with the overall FD phe-
notype compared with asymptomatic controls was not
significant (P = 0.117). Thirty-nine subjects had EPS,
whereas 42 had PDS; 28 subjects simultaneously had EPS
and PDS (Table 1). When the subtypes of FD and the
genotypes were exploratory evaluated, a significant asso-
ciation of genotype in PDS subjects compared to that in
control was detected (P = 0.019). On the other hand, no
association of genotype in subjects with the EPS pheno-
type compared to that in controls was detected. The
odds ratios of the 5-HTTLPR SL and LL genotypes rela-
tive to the SS genotype for the phenotypes of FD, EPS,
PDS are shown in Table 2. Significant associations were
detected for the SL genotypes in the PDS subtype [odds
ratio (OR) = 2.24, 95% confidence interval (CI); 1.16-4.32,
P = 0.033 after Bonferroni correction] adjusted for sex
and age (Table 2). Comparison of the SS genotype with
the SL/LL genotype also showed a significant association
of genotype (OR = 2.32, 95% CI; 1.23-4.37, P = 0.009)
(Table 2). However, there was no significant association
of genotype detected in the FD and EPS phenotypes.
Discussion
I nt h ep r e s e n ts t u d y ,t h ep r e v a l e n c eo ft h e5-HTTLPR
polymorphism was examined in dyspeptic patients in a
Japanese population. Although the power was not
enough for the analysis and the data are preliminary, the
Table 1 Participant demographics and genotype distributions
Controls (n = 646) FD, total (n = 53) P
2 EPS (n = 39)
4 P
2 PDS (n = 42)
4 P
2
Age (years)
1 45 (19-78) 52 (21-82) 0.002 50 (21-82) 0.021 51 (21-82) 0.015
Sex (male%) 50.5 49.1 0.887 41.0 0.323 52.4 0.874
Smoking (%) 32.7 28.3 0.647 23.1 0.289 31.0 1.000
Drinking (%) 29.6 32.1 0.755 30.8 0.858 33.3 0.604
5-HTTLPR genotype (%)
SS 69.3 56.6 61.5 50.0
SL 26.9 37.7 30.8 42.9
LL 3.7 5.7 0.117 7.7 0.257 7.1 0.019
P for HWE
3 0.173 0.889 0.405 0.746
1Data are shown as median (range).
2P vs. controls by Mann-Whitney U-test (for age) or Fisher’s exact test (for other variables).
3P for deviation from Hardy-Weinberg equilibrium (HWE).
4Twenty eight subjects are simultaneously classified EPS and PDS phenotype.
FD, functional dyspepsia; EPS, epigastric pain syndrome; PDS, postprandial distress syndrome
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risk of PDS. Camilleri et al. and van Lelyveld et al.
reported that the 5-HTTLPR polymorphism was not
associated with dyspepsia in a population in the US and
the Netherlands [33,34]. The SERT mRNA expression in
the gastric specimens of pediatric age FD patients was
not significantly different compared with healthy controls
[37]. These contrasting observations may be explained by
differences in the genotypic composition of populations
in different countries with different racial groups. In fact,
the frequency of the LL subtype is lower in the Japanese
population than in Caucasian populations [35,36]. In
addition, the definition of FD or sample selection may
also affect the outcome. Moreover, the effect of type II
error cannot be excluded in relatively small sample sizes.
Another limitation of this study was that the ages were
different in the groups. However, age adjustment was
performed in genotype analysis using logistic regression.
The SERT is the target of selective serotonin re-uptake
inhibitors (SSRI), which are widely used as antidepressants.
Although SSRIs have been reported to have a benefit in
IBS [38], few trials have focused on FD treatment. Any evi-
dence of effectiveness is weak to nonexistent. Wu et al.
conducted an open clinical trial with 40 FD patients. They
reported that fluoxetine improved symptom scores in
depressive FD patients [39]. Van Kerkhoven et al. con-
ducted a randomized controlled trial with venlafaxine in
160 FD patients and showed no significant difference com-
pared with placebo [40].
The results of the present study suggest the hypothesis
that the 5-HTTLPR L allele may be associated with PDS.
Based on in vitro studies of 5-HTTLPR polymorphism
function, excessive transcription of SERT in 5-HTTLPR L
allele would be expected to lead to higher 5-HT reuptake
activity and decreased levels of 5-HT in the synaptic cleft
[20], which in turn might result in decreased gut motility
and secretion, subsequently causing postprandial fullness
and early satiety, which are PDS symptoms. Actually
after excluding subjects with both EPS and PDS, the
association of SL genotype for the development of PDS
was stronger (data not shown). However, the power was
too small to conclude this from the present study.
Furthermore, multiple testing may also affect the results.
Therefore, we cannot exclude the effect of type I error.
The secreted 5-HT affects at least 30 subtypes of 7
main subclasses of serotonergic receptors that cause var-
ious effects on the gut or brain. There are several reports
about the association between specific serotonergic
receptors and dyspepsia. We have reported that the
5HT1A agonist tandospirone improved abdominal symp-
tom scores, including upper abdominal pain and discom-
fort [41]. On the other hand, Tack et al. reported that a
5HT1A agonist failed to improve symptoms, visceral
hypersensitivity, or gastric accommodation compared
with placebo [42]. Boeckxstaens et al. also reported that a
5HT1A agonist had no effect on gastric fundus disten-
sion-evoked dyspeptic symptoms in healthy volunteers
[43]. Talley et al. reported that alosetron, a 5HT3 antago-
nist, had potential benefit in relieving functional dyspep-
sia symptoms compared to placebo [44]. Maxton et al.
and Kuo et al. also reported the effectiveness of alosetron
for FD symptoms [45,46]. In addition, Vakil et al.
reported in their meta-analysis that tegaserod, a 5HT4
agonist, showed significant benefit in dysmotility, as
occurs in FD [47].
Some reports seem to support our hypothesis, but there
are several conflicting results. Therefore, the role of SERT
functional differences in the gut is still unclear. The
Table 2 Risk of dyspepsia according to 5-HTTLPR genotypes
FD, total (n =
53)
EPS (n = 39)
1 PDS (n = 42)
1
OR (95%CI) P
uncorrected
(corrected)
OR (95%CI) P
uncorrected
(corrected)
OR (95%CI) P
uncorrected
(corrected)
5-HTTLPR
genotype
SS 1 reference 1 reference 1 reference
SL 1.75 (0.96-
3.19)
0.672
(1.000)
1.33 (0.65-
2.73)
0.443
(0.886)
*2.24 (1.16-4.32) 0.017
(0.033)
LL 2.12 (0.59-
7.59)
0.250
(0.499)
2.50 (0.69-
9.10)
0.164
(0.328)
3.02 (0.83-
11.06)
0.094
(0.188)
Recessive model
SS vs. SL+LL 1.79 (1.01-
3.18)
0.472 1.46 (0.75-
2.87)
0.268 *2.32 (1.23-4.37) 0.009
1Twenty eight subjects are simultaneously classified EPS and PDS phenotype.
FD, functional dyspepsia; EPS, epigastric pain syndrome; PDS, postprandial distress syndrome;
OR, sex- and age-adjusted odds ratio, vs. 646 controls, by a multiple logistic regression model; CI, confidence interval.
* Significant P < 0.05
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morphism have been investigated in a report concerning
IBS. However, there are many conflicting results [48].
Some studies have reported a sex relation in 5-
HTTLPR polymorphism. Yeo et al. reported a significant
association between D-IBS and 5-HTTLPR SS genotype
in females [26]. A similar result for anxiety traits was
reported by Mizuno et al. Females with the L/S geno-
type showed higher anxiety scores than males [49].
However, the sample size of this study was too small to
conclude that there was a sex difference.
Conclusion
We have exploratory shown that 5-HTTLPR L allele may
influence the susceptibility to PDS in a Japanese popula-
tion. This is the first report that shows the possibility of a
significant association between PDS and 5-HTTLPR poly-
morphism. FD is a complex and heterogeneous disorder,
a n di ti sk n o w nt h a tF Di sn o tc a u s e db yas i n g l eg e n e .
Additional studies with a further larger sample and dif-
ferent polymorphisms are mandatory to identify the
genetic background that influences susceptibility to FD.
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